41,484 Shares in AtriCure, Inc. $ATRC Purchased by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, Holdings Channel.com reports. The firm purchased 41,484 shares of the medical device company’s stock, valued at approximately $1,161,000.

A number of other hedge funds have also recently bought and sold shares of the business. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at approximately $37,000. Smartleaf Asset Management LLC grew its position in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure in the second quarter worth $40,000. Allworth Financial LP bought a new stake in shares of AtriCure in the second quarter worth $43,000. Finally, Fifth Third Bancorp acquired a new stake in AtriCure in the first quarter valued at $51,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Trading Down 1.0%

AtriCure stock opened at $48.17 on Thursday. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $49.88. The firm’s 50-day moving average is $37.09 and its 200-day moving average is $32.06. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market cap of $2.45 billion, a P/E ratio of 229.39 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the prior year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Justin J. Noznesky sold 6,182 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the transaction, the insider directly owned 100,219 shares in the company, valued at $3,888,497.20. This represents a 5.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karl S. Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock valued at $2,149,994 over the last 90 days. 4.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on ATRC. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $48.62.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.